Cooperation in R&D in the pharmaceutical industry: Technological and clinical trial networks in oncology

2022 ◽  
Vol 176 ◽  
pp. 121426
Author(s):  
Giovana Maria Lanchoti Fiori ◽  
Fernanda Gisele Basso ◽  
Geciane Silveira Porto
Keyword(s):  
Clinical Trial ◽  
Pharmaceutical Industry

Improvement in clinical trial disclosures and analysts’ forecast accuracy: evidence from the pharmaceutical industry

2016 ◽  
Vol 49 (3) ◽  
pp. 785-810 ◽  
Author(s):  
Maggie Hao ◽  
Dana A. Forgione ◽  
Liang Guo ◽  
Hongxian Zhang
Keyword(s):  
Clinical Trial ◽  
Pharmaceutical Industry ◽  
Forecast Accuracy

Medical Communications in an Agency Setting: A Career Option for Pharmacists

2021 ◽  
pp. 089719002098713
Author(s):  
Samantha Miernicki ◽  
Gregory Anagnostos ◽  
Joseph P. Nathan ◽  
Sara Grossman
Keyword(s):  
Clinical Trial ◽  
Pharmaceutical Industry ◽  
Opinion Leaders ◽  
Brand Identification ◽  
Advisory Boards ◽  
Career Option ◽  
Key Characteristics ◽  
Key Opinion Leaders ◽  
Video Presentations

Medical communications (MedComms) agencies serve the varied needs of the pharmaceutical industry and other healthcare-related organizations. These agencies present a unique practice opportunity for pharmacists who possess the requisite knowledge and skillset to flourish and grow professionally in this environment. Published information about this sector of the industry is limited. To this end, this article provides an overview of the MedComms agency setting and describes the services provided by such agencies. These include the development of branded and/or unbranded communications materials in the form of publications, oral and video presentations, slide decks, and other materials. MedComms professionals also facilitate and support professional meetings and presentations, such as congresses, symposia, and advisory boards. Other services that MedComms agencies provide include engaging key opinion leaders, providing clinical trial services, and brand identification or positioning. The article describes the opportunities for pharmacists in this field, key characteristics and skills needed to succeed in this industry, and the pathway for pharmacists to enter this field.

Aiming for Excellence

2014 ◽  
Author(s):  
Michael Tansey
Keyword(s):  
Clinical Trial ◽  
Pharmaceutical Industry ◽  
Clinical Research ◽  
Performance Metrics ◽  
Poor Performance ◽  
Clinical Development ◽  
Common Denominator ◽  
Operational Environment ◽  
The Poor ◽  
Intelligent Behavior

Clinical trial processes are what we repeatedly do in clinical research, but, unfortunately, the habit of excellence is not as prevalent as it might be. Processes are only as good as the ways in which they are carried out, so this aspect is worth looking at before examining the processes themselves. Excellence means the very best that is achievable in a given situation with the knowledge and resources available, and it is not to be confused with perfection, which is rarely attainable, and trying to achieve it is a waste of time. Although the rational implementation of the various approaches described later can help to make the clinical development process significantly more efficient, this will not in itself achieve excellence. Implementation needs to take place in a cultural, intellectual, and operational environment that lends the necessary support. There are many possible components of such an environment, but one can go far by • instituting some basic behavioral elements; • doing things as well as they can be done all the time; • simplifying processes; • not allowing regulations to develop into liabilities. I have included this section risking that it might be considered unnecessary and patronizing by some. After all, everybody believes that their behavior is impeccable, just as everybody is a perfect driver. It only takes a few people to behave badly to poison an organization (or to injure others). . . . Laws control the lesser man. Right conduct controls the greater one. . . . . . .—Chinese proverb. . . . . .Good behavior is the last refuge of mediocrity.. . . . . . —Henry S. Haskins, stockbroker who was expelled for alleged misconduct and published his aphorisms anonymously. . . Can principles be applied that encourage positive, ethical, complex, and intelligent behavior without retreating into the lowest common denominator of mediocrity? One can argue the extent to which principles can help to achieve these objectives, but what is undeniable is that, in their absence, the results can be extremely damaging. This is exemplified not only by the poor performance metrics but also by the poor reputation of the pharmaceutical industry in the public’s view.

Blockchain Pharma

2021 ◽  
pp. 312-329
Author(s):  
Francisco Ribeiro de Sousa
Keyword(s):  
Clinical Trial ◽  
Supply Chain ◽  
Intellectual Property ◽  
Pharmaceutical Industry ◽  
Property Rights ◽  
Semantic Web ◽  
Intellectual Property Rights ◽  
Cryptographic Protocol ◽  
Advanced Country ◽  
Trial Protocols

Blockchain, a distributed ledger technology (DLT) that sustained the creation of the first digital currency, Bitcoin, crosses many business areas, including healthcare, to promise better economic solutions. Blockchain generalized implementation is already a reality in Estonia, perhaps the most digitally advanced country globally, with proven healthcare results for its citizens. From a pharmaceutical industry perspective, blockchain offers solutions as diverse as the structuring of clinical trial protocols, the traceability of medicines along the supply chain, and intellectual property rights. Additionally, the DLT's cryptographic protocol, whose main characteristics are immutability, consensus, security, and transparency, may support both the web's decentralization and the transition to a Semantic Web, which is recognized by many as highly recommended.

History of Clinical Trial Development and the Pharmaceutical Industry

2010 ◽  
Author(s):  
Jeffrey Peppercorn ◽  
Thomas G. Roberts ◽  
Tim G. Hammond
Keyword(s):  
Clinical Trial ◽  
Pharmaceutical Industry ◽  
History Of

Developing a clinical trial governance framework for pharmaceutical industry-funded clinical trials

2018 ◽  
Vol 25 (7-8) ◽  
pp. 373-386
Author(s):  
Satish Chandrasekhar Nair ◽  
Shamsa AlGhafli ◽  
Ayesha AlJaberi
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Pharmaceutical Industry ◽  
Governance Framework
Sign in / Sign up

Export Citation Format

Share Document